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Abstract  
Canine cognitive dysfunction syndrome (CDS)  is a neurodegenerative disorder of aged dogs 
characterized by a progressive decline in cognitive function. In humans and laboratory animals a 
variety of neurotransmitter abnormalities have been described in patients affected by age-related 
dementia. Specifically, the regulatory role of the catecholaminergic, serotonergic and cholinergic 
systems have been outlined. The aim of the present study was to measure blood monoamine levels, 
platelet 2-adrenergic receptors  and lymphocyte muscarinic receptors  in healthy adult and old 
dogs and in dogs affected by canine cognitive dysfunction. Based on clinical and behavioral 
examination, 40 dogs were divided into three groups: healthy adults (n=14), old dogs (n=17), and 
old dogs affected by canine cognitive dysfunction (n=9). A significant reduction in plasma levels of  
norepinephrine and dopamine was observed both in aged (0.16±0.02 ng/mL; P<0.01 and 0.11±02 
P<0.01 respectively) and CDS dogs (0.14±0.03 ng/mL; P<0.05 and 0.10±00.005 P<0.01 
respectively) compared to adults (0.29±0.04 ng/mL and 0.15±0.02 respectively). No  significant 
differences were observed among groups for 2-adrenergic receptor concentrations. Canine 
lymphocytes express two distinct classes of muscarinic receptors, characterized by high (HA) and 
low (LA) affinity for 3H-N-methyl-scopolamine. A significant age-dependent decrease in HA 
muscarinic receptors was observed. However, no differences were found between old (87.65±11.08 
sites/cellx102) and CDS dogs (90.17±6.75 sites/cellx102 ). As far as LA muscarinic receptors are 
concerned, CDS dogs showed a significant increase (393.48±63 sites/cellx102; P<0.05)  with 
respect to adults (188.84±16.50 sites/cellx102 ). Our results suggest that the reduction in HA 
muscarinic receptor binding sites could be representative of the physiological ageing process, 
whereas the increase in lymphocyte LA muscarinic receptor levels could be related to the cognitive 
decline.  
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 Introduction 
Ageing represents a complex biological process characterized by a progressive degeneration of  
tissues and cells with a gradual loss of adaptive capacity. In human aging it is generally  associated  
with  a decline  in  a range of cognitive  functions,  including learning,  memory,  visuospatial  
function,  language,  information  processing  speed,  and  executive function (Adams et al., 2000). 
 In  ageing animals a decrease in learning and memory performance can be observed (Milgram et 
al., 1994; Landsberg and Ruehl, 1997; Adams et al., 2000; Chan et al., 2002). A serious impairment 
of  cognitive processes has to be distinguished from a simple and mild decrease of the psychomotor 
activity and may be considered as “pathological ageing” (Adams et al., 2000). As in humans, where 
different levels of ageing and dementia have been classified, various authors have described the so-
called “canine cognitive dysfunction syndrome” (CDS) (Landsberg, 2005; Milgram et al., 1994; 
Cummings et al., 1996a,b). The term canine cognitive dysfunction is used in the veterinary 
literature to describe a progressive neurodegenerative disorder of aged dogs that is characterized by 
a gradual decline in cognitive functions such as learning, memory, perception, and 
awareness (Landsberg, 2005; Milgram et al., 1994; Cummings et al., 1996a,b).  
In humans and laboratory animals a variety of neurotransmitter abnormalities have been 
described in patients affected by age-related dementia (Rehman and Masson, 2001; Buccafusco, 
2006; Hirata-Fukae et al., 2008). Nevertheless, these modifications are often associated with 
specific diseases such as Parkinson’s and Alzheimer’s diseases (AD) and their involvement in the 
pathogenesis of age-related cognitive dysfunctions has not been fully elucidated to date (Rehman 
and Masson, 2001). Ageing has been associated with a decrease in central nervous system 
dopamine (D) and dopamine receptor (DR) levels and, interestingly, in Alzheimer’s disease affected 
patients a decrease in brain 2-adrenoceptors (2-AR) has been documented (Kalaria et al., 1989; 
Kalaria and Andorn, 1991; Meana et al., 1992; Sastre et al., 2001).  
The serotonergic system seems to be involved in the physiological process of ageing and in 
the pathogenesis of Alzheimer’s disease. In fact, the central nervous system serotonin levels 
decrease with age, and in AD patients a significant decrease of the neurotransmitter and of some of 
its metabolites has been observed in the central nervous system and in the cerebrospinal fluid 
(Baker and Reynolds, 1989; Reinikainen et al., 1990; Tohgi et al., 1992). The change in serotonin 
levels has been associated with modifications of serotonin receptor concentrations (Lai et al., 2002). 
It has been suggested that platelets represent a suitable peripheral marker of central serotonergic 
activity as in AD subjects a significant decrease of central and platelet serotonin concentrations was 
observed (Kumar et al., 1995; Inestrosa et al., 1993). 
According to the “cholinergic hypothesis” of human ageing and Alzheimer’s disease, the 
dysfunction of the cholinergic system contributes to the memory and cognitive decline. The 
hypothesis has been supported by pharmacological and histological evidence (Bartus et al., 1982; 
Dunnet and Fibiger, 1993; Araujo et al., 2005). It has been observed that the administration of the 
muscarinic antagonist scopolamine induces a cognitive impairment in healthy young humans 
(Drachman and Leavitt, 1974; ) and this is increasingly disruptive with advancing age and declining 
cognitive status (Tariot et al., 1996). Similar findings have been observed in primates, rodents and, 
more recently, in dogs (Bartus, 2000; Pilcher et al., 1997; Biggan et al., 1996; Araujo et al., 2004). 
Moreover, in Alzheimer’s disease a remarkable decrease of choline acetyltransferase activity in the 
cerebral cortex and hippocampus has been observed (Davies and Maloney, 1976; Bowen et al., 
1997). A correlation between the loss of cortical synapses and cognitive decline was demonstrated 
as well as a close relationship between this loss and the decrease of high-affinity cholinergic 
receptors (Withehouse et al., 1982; Nordberg et al., 1992; Hellstrom-Lindahal et al., 1999). Several 
papers have reported a decrease in muscarinic receptor concentrations in different areas of the 
central nervous system in both aged humans and rats (Mulugeta et al., 2003; Tayebati et al., 2004; 
Norbury et al., 2005; Karanth et al., 2007). Furthermore, Tayebati et al. (2001) demonstrated that 
AD patients show a decrease in lymphocyte muscarinic receptors3 subtype and an increase in the 
muscarinic receptors4 subtype (Tayebati et al., 2001).  
It  has been suggested that canine ageing is similar to some extent to human ageing and that 
neuropathological changes that occur in dogs are similar to those seen in human aging and in  
Alzheimer’s disease (Studzinski et al., 2005).  Aged dogs, like humans,  naturally develop amyloid-
 deposition and the sequence of the gene encoding for this protein is identical to the human one 
(Azizeh et al., 2000; Head, 2001). Moreover, dogs and humans share similar patterns of cognitive 
decline as a function of age (Adams et al., 2000). As a consequence, the dog model is effective in 
predicting cognitive modifying effects of drugs (Studzinski et al., 2005). Nevertheless, the 
neurotransmitter systems involved in the pathogenesis of canine cognitive syndrome have not been 
fully elucidated to date.  
Based on this background, the aim of the present study was to measure blood monoamine 
levels, platelet 2-adrenergic receptors and lymphocyte muscarinic receptors in healthy adult and 
old dogs, and in dogs affected by canine cognitive syndrome to identify peripheral markers of the 
disease and possible targets for specific pharmacological treatments. Previous studies have 
demonstrated that radioligand binding assays allow the measurement of specific receptor 
concentrations in different organs and tissues of domestic animals (Badino et al., 2004;  Badino et 
al. 2005). 
 
 
 Material and methods 
 
Animals   
Dogs were selected on the basis of  history, neurological, cardiology and behavioral examination 
out of over 124  animals referred to the Teaching Hospital of the Faculty of Veterinary Medicine of 
the University of Turin. The study was carried out on 40 dogs (26 males and 14 females; weight  
15 Kg). To fulfill the inclusion criteria, the age ranged from 2 to 8 years for the adult group, 
whereas dogs more than 9 years old were considered as aged. Exclusion criteria were primary organ 
failure and/or neurological signs. To evaluate the physical condition of dogs, standard clinical 
examination and laboratory assessments (complete blood count, basic biochemical profile, 
urinalysis, basic endocrine screening to asses thyroid function) were performed. Moreover,  
neurological and cardiology examinations have been carried out. In order to diagnose canine 
cognitive syndrome, the cognitive status of each dog was checked by the veterinary behaviorist 
filling in a questionnaire (Osella et al., 2007)  on the basis of the owners’ answers and using  
cognitive tests aimed to evaluate the short-term visuo-spatial memory (Ghi et al., 2009). Based on 
clinical and cognitive examinations, dogs were divided into 3 groups: GROUP 1: healthy adults 
(n=14; age range 2-8 years, mean  SE 4.3  0.5 years, median 4.5 years); GROUP 2: healthy old 
dogs (n=17; age range 9-14, mean  SE 10.5  0.4 years, median 11 years), and GROUP 3: old 
dogs affected by canine cognitive dysfunction (n=9; age range 9-15 years, mean  SE 12.0  0.8 
years; median 12 years).  
All the procedures and sample collections were conducted according to ethical guidelines 
laid down by the University of Torino (86/609/EEC). 
 
2.3 Blood sample collection and lymphocyte and platelet separation 
To obtain suitable biological samples minimizing discomfort to dogs, a method of platelet and 
lymphocyte separation from a small volume blood aliquot was developed. Twenty ml blood 
samples were drawn from each dog in tubes containing Na-EDTA. Samples were immediately 
centrifuged at 240 x g for 20 min at room temperature to obtain the platelet rich plasma (PRP) 
fraction. The harvested PRP fractions were then ultra-centrifuged at 35 000 x g for 20 min at 4°C 
and the resulting pellets were re-suspended in a specific assay buffer (50 mM Tris-HCl, 0.5 mM 
MgCl2; pH 7.4) and stored at –80°C until the 2-adrenergic receptor binding assay was run (Pelat et 
al., 2001). 
After removing the platelet rich plasma, the remaining blood was diluted with 2.5 ml of 
Hank’s Balanced Salt Solution (HBSS) and layered into tubes containing 2 ml of Histopaque 1119 
(bottom) and 2 ml of Histopaque 1077 (2 ml of blood and 4 ml of Histopaque). Tubes have been 
centrifuged at 340 x g for 30 min at 4°C and the resulting buffy coats, layered between plasma and 
Histopaque 1077, were centrifuged at 1 660 x g, washed twice with HBSS, re-suspended in saline 
solution (0.9% NaCl; room temperature), counted in a cell counter and stored at –80°C until 
muscarinic receptor binding assay (Re et al., 1999). 
 
Platelet 2-adrenergic receptor binding assay 
Platelet 2-adrenergic receptor concentration was assessed using the method described by Pelat et 
al. (2002), but introducing some minor modifications. Briefly, aliquots of platelet suspension (1.5 
mg of protein/ml) were incubated for 30 min at 25°C with increasing concentrations (0.07-10 nM) 
of 3H-RX821002, a specific ligand for 2-adrenergic receptors. Non-specific binding was 
evaluated by adding 20 M norepinephrine to the incubating mixture. Incubation was stopped by 
adding 2 ml of ice-cold buffered saline solution (154 mM NaCl, 50 mM Tris-HCl; pH 7.4) and the 
incubation mixtures were immediately filtered under vacuum over pre-soaked glass microfiber 
filters. The filters were then washed with buffered saline and solubilized with 4 ml of scintillation 
fluid (PicoFluor 40, Perkin Elmer). The radioactivity was measured by the use of a -counter. 
 
 Lymphocyte muscarinic receptor binding assay 
Measurements of muscarinic receptor were performed as described by Tayebati et al. (1999) with 
some minor modifications. Aliquots of lymphocyte suspension (1 x 106 cells) were incubated for 1 
h at 25°C with increasing concentrations (0.03-4 nM) of 3H-N-methyl-scopolamine. Non-specific 
binding was measured in the presence of an excess of atropine (12 M). At the end of the 
incubation, samples were processed as described for the platelet 2-adrenergic receptor binding 
assay. 
 
 Catecholamine and serotonin blood levels 
Epinephrine, norepinephrine and dopamine plasma levels were measured using a commercial RIA 
kit (TriCat, IBL), whereas serotonin serum concentrations were assessed using a commercial 
ELISA kit (Serotonin ELISA, IBL) (Badino et al., 2009) 
 
 Processing and statistical analysis of data 
The equilibrium dissociation constant (Kd) and the number of binding sites (Bmax), expressed as nM 
and femtomoles of specifically bound ligand/mg of membrane protein (2-adrenergic receptors) or 
sites/cells x 102 (muscarinic receptors), respectively, were calculated by computerized Scatchard 
analysis (GraphPad Prism). Saturation radioligand binding experiments measure specific 
radioligand binding at equilibrium at various concentrations of the radioligand and allow the 
determination of both receptor concentration and radioligand affinity. In the Scatchard plot, the  X-
axis is the specific binding (Bs) and the Y-axis is specific binding divided by free radioligand (F) 
concentration (Bs/F) calculated at each concentration of radioligand.  It is possible to estimate the 
Bmax and Kd from a Scatchard plot (Bmax is the X intercept; Kd  is the negative reciprocal of the 
slope). The Bmax value is the highest concentration of radioligand specifically bound to the receptor 
and represents a measure of receptor concentration.  The Kd value is the concentration of 
radioligand in which a half of receptor is occupied and characterizes the affinity and specificity of 
the ligand for the receptor (Scatchard, 1949). 
Results were expressed as mean values  SEM (mean standard error). Statistical analysis consisted 
of multiple comparisons using Tukey-Kramer adjustments to avoid inflation of Type I error due to 
multiple comparisons (GraphPad Instat). 
 
Results 
Platelet 2-adrenergic receptor concentrations 
Scatchard analysis demonstrated the presence of a single class of binding sites saturated by the 
radioligand concentrations used. Platelet 2-adrenergic receptor levels and Kd values are shown in 
Table 1. No  significant differences were observed among groups both for 2-adrenergic receptor 
concentrations and Kd values.  
 
 Lymphocyte muscarinic receptor concentrations 
Scatchard analysis allowed identifying in all groups of dogs two distinct receptor binding sites of 
lymphocyte muscarinic receptors. They were characterized by significant differences in Kd values 
(Table 2) resulting in high affinity (HA) and low affinity (LA) muscarinic receptors. The 
muscarinic receptor concentrations are reported in Table 3. Statistical analysis showed significant 
differences in HA muscarinic receptor levels between GROUP 1  and GROUP 2  dogs (P<0.01) and 
between GROUP 1 and GROUP 3 dogs (P<0.05). Significant differences were observed in LA 
muscarinic receptor concentrations between GROUP 3 and GROUP 1 dogs (P<0.05). 
 
 Catecholamine and serotonin blood levels 
Table 4 summarizes blood monoamine levels (epinephrine, norepinephrine, dopamine and 
serotonin) in healthy and affected dogs. A significant decrease in norepinephrine and dopamine 
plasma levels was observed between GROUP 1 and GROUP 2  dogs (P<0.01) and between 
GROUP 1 and GROUP 3 dogs (P<0.05 and P=0.01, respectively), whereas no  significant 
difference was found between GROUP 2 and GROUP 3 dogs.  
 
Discussion 
Data reported  in the present study suggest the presence of measurable concentrations of 2-
adrenergic receptors in platelets and muscarinic receptors in lymphocytes of dogs. The binding 
method used in our experiment allowed us to identify two distinct classes of lymphocyte muscarinic 
receptors, characterized by high and low affinity for radioligand. However, the non selective 3H-
N-methyl-scopolamine did not allow us to characterize the different muscarinic receptor subtypes. 
Currently, five muscarinic receptor subtypes have been identified (M1-M5 receptors). While the 
odd-numbered receptors (M1, M3, and M5) activate phospholipase C (PLC) leading to 
phosphatidylinositol 4,5-biphoshonate hydrolysis, agonist activation of even receptors (M2 and M4) 
leads to adenylyl cyclase inhibition (Ishii and Kurachi, 2006). In the brain of human beings affected 
by Alzheimer’s disease, molecular biology analysis revealed a decrease in M1R and M2R and an 
increase in M4 subtypes (Flynn et al., 1995), whereas pharmacological assays demonstrated a 
decrease in M1R-M3R (Rodriguez-Puertas et al., 1997). More recently, Araujo et al., (2011) found 
that scopolamine significantly impairs performance of aged dogs and that senior dogs show a 
decreased density of muscarinic receptors in different brain areas. Nevertheless, few studies 
investigating neurochemical changes and cholinergic dysfunction during canine ageing have been 
published to date (Woodruff-Pak, 2008). Our data suggest that modifications in lymphocyte 
muscarinic receptor concentrations reflect those observed in the central nervous system of old dogs. 
As a consequence, circulating lymphocytes could represent a marker of central cholinergic activity 
thus allowing in vivo studying  of cholinergic function in dogs (Bany et al., 1999; Tayebati et al., 
1999; Kawashima and Fujii, 2004). In human beings several studies reported that in cognitive 
dysfunctions, such as Alzheimer’s disease or Parkinson’s disease, lymphocyte muscarinic receptor 
concentrations decrease (Ferrero et al., 1991; Rabey et al., 1991). More specifically, AD patients 
show a decrease in the lymphocyte M3R and an increase in the M4R subtypes (Tayebati et al. 
2001). To the best of our knowledge, studies concerning the fluctuation of lymphocyte muscarinic 
receptors in canine cognitive dysfunction are lacking. 
In our study a significant age-dependent decrease in high affinity muscarinic receptors has 
been observed, however no differences were found between old and CDS dogs. The latter showed a 
significant increase in low affinity muscarinic receptor concentrations when compared with adult. 
These findings suggest that the reduction in high affinity binding sites could be representative of the 
physiological ageing process, whereas the increase in lymphocyte LA muscarinic receptor levels 
could be related to the cognitive decline.  
In human medicine several studies have been performed  to evaluate the involvement of the 
adrenergic system in Alzheimer’s disease. Despite the fact that some results seem to be 
controversial, some authors observed a decrease in brain 2-adrenergic receptor concentrations in 
AD patients (Kalaria et al., 1989; Kalaria and Andorn, 1991; Meana et al., 1992; Sastre et al., 
2001). By contrast, Pfeifer et al. (1984) suggested that there is no correlation between age and the 
number of platelet 2-adrenergic receptors and between plasma levels of catecholamines and 
platelet 2-adrenergic receptors.  Present data seem to suggest that neither ageing nor cognitive 
impairment alter platelet 2-adrenergic receptor concentrations in dogs.  
A variety of neurotransmitter abnormalities have been described in patients affected by age-
related dementia. Despite the fact that the most studied neuronal system dysfunction is represented 
by the cholinergic system, evidences support the involvement of  the adrenergic and the 
serotonergic systems too (Hermann et al., 2004).  
The locus ceruleus is the major nucleus of origin of noradrenergic neurons in the 
mammalian brain (Lanari et. al, 2006). This brainstem nucleus is probably involved in sleep, 
attention, memory, and vigilance. Several studies have demonstrated greater locus ceruleus neuron 
loss in subjects with Alzheimer’s disease (Hoogendijk et al., 1999; Storga et al., 1996; Matthews et 
al., 2002) and similar findings have been observed in dogs with cognitive impairment (Insua et al., 
2010). These changes in the locus ceruleus may account for a deficiency in the noradrenergic 
system in the pathogenesis of Alzheimer’s disease. Central norepinephrine levels have also been 
found to have an inverse relationship with cognitive impairment (Matthews et al., 2002). Data 
obtained in the present study demonstrated a significant reduction in norepinephrine plasma levels 
in both aged dogs and dogs affected by canine cognitive dysfunction compared to controls. This 
finding is only partially in agreement with data reported in the literature, as we did not observe 
differences between old and CDS dogs.  
In the central nervous system serotonin is synthesized and stored in the presynaptic neurons 
located in nine groups of cell isolated from the pons and midbrain. The raphe nuclei represent the 
major nuclei with both ascending serotonergic fibres projecting to the forebrain and descending 
fibres that extend to the medulla and spinal cord. Serotonin has been linked to different central 
nervous system functions such as mood, behavior, sleep cycle, and appetite (Mohammad-Zadeh et 
al., 2008). Neurochemical and neuropathological disruptions in the serotonergic system such as 
decreased concentrations of both serotonin and its major metabolite (5-hydroxyindoleacetic acid) in 
the temporal cortex (Zubenko et al., 1991; Lanctot et al., 2001) have been recognized in the 
Alzheimer’s disease.  Studies concerning platelet serotonin concentrations in AD patients yielded 
controversial results as increased, decreased or unaltered levels have been observed (Kumar et al., 
1995; Meszaros et al., 1998; Mimica et al., 2005). However, according to Muck-Seler et al. (2009) 
differences in peripheral serotonin levels depend on the severity and/or clinical progress of 
Alzheimer’s disease and no significant correlation exists between age and platelet serotonin 
concentration. As such, the lack of statistically significant differences in blood serotonin levels 
between adult and CDS dogs observed in our study could be ascribed to the limited number of 
pathological animals that did not allow a further subdivision according to the severity of cognitive 
impairment. 
To conclude, results of the present study represent the first direct evidence of the 
involvement of the cholinergic system in canine physiological and pathological ageing. This 
supports the use of the aged dog as a natural model for examining pathogenetic hypotheses in the 
development of Alzheimer's disease. Furthermore, our data demonstrate that muscarinic receptors 
are possible targets for specific drug treatment in dogs affected by cognitive dysfunction.  
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Table 1. 2-AR (2 adrenergic receptors) concentrations (fmol/mg of protein) and Kd values (nM)  
 2-AR 
fmol/mg of protein 
Kd 
nM 
Group 1 230  24 0.4  0.05 
Group 2 287  28 0.3  0.04 
Group 3 290  36 0.4  0.05 
 
Group 1: adult dogs (n=14); Group 2: old dogs (n= 17); Group 3: CDS old dogs ( n=9). 
Results are expressed as mean values  SEM. 
 
 
Table 2. Kd values (nM) of MR (muscarinic receptors)  
 Kd MRHA 
nM 
Kd MRLA 
nM 
P values 
 
Group 1 0.09  0.02 0.8  0.19 < 0.05 
Group 2 0.06  0.01 1.0  0.20 < 0.001 
Group 3 0.09  0.02 0.9  0.15 < 0.05 
 
Group 1: adult dogs (n=14); Group 2: old dogs (n= 17); Group 3: CDS old dogs ( n=9). MRHA: 
high affinity binding sites; MRLA: low affinity binding sites. Results are expressed as mean values 
 SEM. 
 
 
 
Table 3. MR (muscarinic receptors) concentrations (sites/cell x 102)  
 Group 1 
sites/cellx102 
Group 2 
sites/cellx102 
Group 3 
sites/cellx102 
Group 2 vs 
Group1 
P values 
Group 3 vs 
Group1 
P values 
Group 2vs 
Group 3 
P values 
MRHA 134.81  7.53 87.65 11.08 90.17  6.75 < 0.01 < 0.05 n.s 
MRLA 188.8416.50 274.38 27.53 392.48 63.47 n.s <0.05 n.s. 
 
Group 1: adult dogs (n=14); Group 2: old dogs (n= 17); Group 3: CDS old dogs ( n=9). MRHA: 
high affinity binding sites; MRLA: low affinity binding sites. Results are expressed as mean values 
 SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Catecholamines (epinephrine, norepinephrine, and dopamine) and serotonin blood levels 
(ng/ml).  
 
 Group 1 
ng/mL 
Group 2 
ng/mL 
Group 3 
ng/mL 
Group 2 
vs 
Group1 
P values 
Group 3 
vs 
Group1 
P values 
Group 3 
vs 
Group2 
P values 
Epinephrine 0.25  0.04 0.20  0.06 0.20  0.05 n.s. n.s. n.s. 
Norepinephrine 0.29  0.04 0.16  0.02 0.14  0.03 < 0.01 < 0.05 n.s. 
Dopamine 0.15  0.02 0.11  0.002 0.10  0.005 < 0.01 < 0.01 n.s. 
Serotonin 332.17  49.92 300.32  34.14 251.51  44.55 n.s. n.s. n.s. 
 
Group 1: adult dogs (n=14); Group 2: old dogs (n= 17); Group 3: CDS old dogs ( n=9). Results are 
expressed as mean values  SEM.  
 
